There are over 400 ongoing clinical trials using tumor-derived vaccines. This approach is especially attractive for many types of brain tumors, including glioblastoma, yet so far the clinical response is highly variable. One contributor to poor response is CD200, which acts as a checkpoint blockade, inducing immune tolerance. We demonstrate that, in response to vaccination, glioma-derived CD200 suppresses the anti-tumor immune response. In contrast, a CD200 peptide inhibitor that activates antigen-presenting cells overcomes immune tolerance. The addition of the CD200 inhibitor significantly increased leukocyte infiltration into the vaccine site, cytokine and chemokine production, and cytolytic activity. Our data therefore suggest that CD200 suppresses the immune system's response to vaccines, and that blocking CD200 could improve the efficacy of cancer immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619161 | PMC |
| http://dx.doi.org/10.2217/imt-2016-0033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combining radiotherapy with targeted therapy benefits patients with advanced epidermal growth factor receptor-mutated non-small cell lung cancer (EGFRm NSCLC). However, the optimal strategy to combine EGFR tyrosine kinase inhibitors (TKIs) with radiotherapy for maximum efficacy and minimal toxicity is still uncertain. Notably, EVs, which serve as communication mediators among tumor cells, play a crucial role in the anti-tumor immune response.
View Article and Find Full Text PDFBecause therapeutic cancer vaccines can, in theory, eliminate tumor cells specifically with relatively low toxicity, they have long been considered for application in repressing cancer progression. Traditional cancer vaccines containing a single or a few discrete tumor epitopes have failed in the clinic, possibly due to challenges in epitope selection, target downregulation, cancer cell heterogeneity, tumor microenvironment immunosuppression, or a lack of vaccine immunogenicity. Whole cancer cell or cancer membrane vaccines, which provide a rich source of antigens, are emerging as viable alternatives.
View Article and Find Full Text PDFSpatiotemporal Nano-Regulator Unleashes Anti-Tumor Immunity by Overcoming Dendritic Cell Tolerance and T Cell Exhaustion in Tumor-Draining Lymph Nodes.
Adv Mater
December 2024
State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, 361005, China.
Lymph nodes are crucial immune foci as the primary target for cancer immunotherapy. However, the anti-tumor functions of tumor-draining lymph nodes (TDLNs) are critically suppressed by tumors. Here, a novel spatiotemporal nano-regulator is presented, designed to modulate the dendritic cells (DCs) in TDLNs, establishing a supportive niche for immune surveillance.
View Article and Find Full Text PDFExosomes as carriers to stimulate an anti-cancer immune response in immunotherapy and as predictive markers.
Biochem Pharmacol
December 2024
Department of Emergency and Critical Care, the Second Hospital of Jilin University, Changchun, China. Electronic address:
Article Synopsis
- Exosomes are small vesicles released by cells that can activate the immune system, making them promising tools in cancer immunotherapy due to their ability to transfer molecules and trigger immune responses.
- They originate from immune and tumor cells, showcasing unique compositions that can influence immune functions and overall cancer progression.
- Understanding how exosomes work in immunotherapy is crucial, as they hold potential as cancer vaccines and targeted drug carriers, offering new strategies to enhance anti-cancer immunity.
Biomimetic Dendritic Cell-Based Nanovaccines for Reprogramming the Immune Microenvironment to Boost Tumor Immunotherapy.
ACS Nano
December 2024
Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China.
Article Synopsis
- Traditional dendritic cell (DC) vaccines face challenges like poor antigen delivery, ineffective lymph node targeting, and risks from living cell transfers.
- The new HybridDC nanovaccine uses engineered DC membranes and anchors multiple components to enhance antigen presentation and boost anti-tumor immunity.
- HybridDC shows improved targeting of lymphoid tissues, effective treatment against glioma models, and enhances the effectiveness of immune checkpoint blockade therapies, suggesting it could revolutionize personalized cancer immunotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!